Chimeric antigen receptor (CAR) T cells have shown impressive therapeutic potential. Due to the lack of direct control mechanisms,
therapy-related adverse reactions including
cytokine release- and
tumor lysis syndrome can even become life-threatening. In case of target
antigen expression on non-malignant cells, CAR T cells can also attack healthy tissues. To overcome such side effects, we have established a modular CAR platform termed UniCAR: UniCAR T cells per se are inert as they recognize a
peptide epitope (UniCAR
epitope) that is not accessible on the surface of living cells. Bifunctional adapter molecules termed target modules (TM) can cross-link UniCAR T cells with target cells. In the absence of TMs, UniCAR T cells automatically turn off. Until now, all UniCAR TMs were constructed by fusion of the UniCAR
epitope to an antibody domain. To open up the wide field of low-molecular-weight compounds for retargeting of UniCAR T cells to
tumor cells, and to follow in parallel the progress of UniCAR T cell
therapy by PET imaging we challenged the idea to convert a PET tracer into a UniCAR-TM. For proof of concept, we selected the clinically used PET tracer
PSMA-11, which binds to the prostate-specific membrane
antigen overexpressed in prostate
carcinoma. Here we show that fusion of the UniCAR
epitope to
PSMA-11 results in a low-molecular-weight
theranostic compound that can be used for both retargeting of UniCAR T cells to
tumor cells, and for non-invasive PET imaging and thus represents a member of a novel class of
theranostics.